Advertisement

Current Tropical Medicine Reports

, Volume 3, Issue 4, pp 138–143 | Cite as

Clinical Characteristics and Treatment of Leprosy

  • Minh Van Hoang
  • Duc Van Bui
  • Thuy Linh PhungEmail author
Tropical Dermatology (TL Phung, Section Editor)
  • 137 Downloads
Part of the following topical collections:
  1. Topical Collection on Tropical Dermatology

Abstract

Purpose of Review

The purpose of this study is to provide an up-to-date review of the clinical presentation, classification system, and treatment of leprosy (also known as Hansen’s disease).

Recent Findings

Leprosy is a chronic infectious disease caused by Mycobacterium leprae. Leprosy affects mainly the skin and peripheral nerves with serious clinical complications, including blindness and physical deformities of the hands and feet. Leprosy is a complex microbial disease with a wide spectrum of clinical presentations and severity of disease progression and outcome. Disease classification based on bacterial indicators and the Ridley-Jopling system are standard classification systems for leprosy that enable proper categorization of different types of leprosy for evaluation and treatment purposes. Early disease detection and treatment can significantly impact the prevalence and severity of leprosy. Long term follow-up as well as disability evaluation and prevention are important measures to prevent disease relapse and to achieve a good clinical outcome for patients.

Summary

Early disease detection, multidrug therapy, frequent clinical follow-up, and proper management of tissue damage and physical disabilities as a result of peripheral nerve damage are key factors to ensure a good outcome for patients.

Keywords

Leprosy Mycobacterium leprae Paucibacillary leprosy Multibacillary leprosy Erythema nodosum leprosum Reversal reaction 

Notes

Acknowledgments

We would like to thank Mahmoud Bokhary, MD, for his valuable assistance with the bibliography of this article.

Compliance with Ethical Standards

Conflict of Interest

Minh Van Hoang, Duc Van Bui, and Thuy Linh Phung declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Yawalkar SJ, editor. Leprosy for medical practitioners and paramedical workers. 8th revised ed. Basle, Swizerland: Novartis Foundation for Sustainable Development; 2009. p. 152.Google Scholar
  2. 2.
    Klaus Wolff RAJ, Saavedra AP, editors. Fitzpatrick’s color atlas and synopsis of clinical dermatology. 7th edition. Color atlas & synopsis of clinical dermatology (Fitzpatrick). New York: McGraw-Hill Medical; 2013. p. 960.Google Scholar
  3. 3.
    Talhari C, Talhari S, Penna GO. Clinical aspects of leprosy. Clin Dermatol. 2015;33(1):26–37.Google Scholar
  4. 4.
    Odom RB, James W, Berger TG, editors. Berger Andrew’s diseases of the skin. Clinical Dermatology: USA; 2000. p. 713.Google Scholar
  5. 5.
    Butlin CR, Saunderson P. Children with leprosy. Lepr Rev. 2014;85(2):69–73.PubMedGoogle Scholar
  6. 6.
    Talwar BH, Nirmala C, Somnath L. Nerve FNAC in diagnosing Hansen’s disease: a prospective study. J Evol Med Dent Sci. 2016;5(15):711–6.Google Scholar
  7. 7.
    Grossetete G et al. Leprosy. Developmental modalities. Rev Prat. 1992;42(5):606–12.PubMedGoogle Scholar
  8. 8.
    • Parkash O. Classification of leprosy into multibacillary and paucibacillary groups: an analysis. FEMS Immunol Med Microbiol. 2009;55(1):1–5. This paper reviews the classification of leprosy based on bacterial burden.Google Scholar
  9. 9.
    • Features of the Ridley-Jopling classification. Int J Lepr Other Mycobact Dis. 1979;47(4): 611–2. This publication describes the widely accepted Ridley-Jopling classification of leprosy based on a combination of clinical, immunologic, bacteriologic and histopathologic characteristics of the disease.Google Scholar
  10. 10.
    Pardal-Fernandez JM et al. Pure neural leprosy. Diagnostic aspects of a clinical case. Rev Neurol. 2016;63(6):257–61.PubMedGoogle Scholar
  11. 11.
    Jardim MR et al. Criteria for diagnosis of pure neural leprosy. J Neurol. 2003;250(7):806–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Bezerra Da Cunha FM et al. Pure neural leprosy: diagnostic value of the polymerase chain reaction. Muscle Nerve. 2006;33(3):409–14.CrossRefPubMedGoogle Scholar
  13. 13.
    Saoji V, Salodkar A. Lucio leprosy with lucio phenomenon. Indian J Lepr. 2001;73(3):267–72.PubMedGoogle Scholar
  14. 14.
    Kim JY, Chung KY, Kim WJ, Jung SY. Lucio phenomenon in non-endemic area of Northeast Asia. J Eur Acad Dermatol Venereol. 2016. doi: 10.1111/jdv.13920.
  15. 15.
    Kaur C, Thami GP, Mohan H. Lucio phenomenon and Lucio leprosy. Clin Exp Dermatol. 2005;30(5):525–7.CrossRefPubMedGoogle Scholar
  16. 16.
    Gupta SK. Histoid leprosy: review of the literature. Int J Dermatol. 2015;54(11):1283–8.CrossRefPubMedGoogle Scholar
  17. 17.
    Walker SL, Lockwood DN. Leprosy type 1 (reversal) reactions and their management. Lepr Rev. 2008;79(4):372–86.PubMedGoogle Scholar
  18. 18.
    Cuevas J et al. Erythema nodosum leprosum: reactional leprosy. Semin Cutan Med Surg. 2007;26(2):126–30.CrossRefPubMedGoogle Scholar
  19. 19.
    Kar HK, Gupta R. Treatment of leprosy. Clin Dermatol. 2015;33(1):55–65.CrossRefPubMedGoogle Scholar
  20. 20.
    • Shen J et al. Six years’ follow-up of multibacillary leprosy patients treated with uniform multi-drug therapy in China. Int J Dermatol. 2015;54(3):315–8. This paper describes the efficacy and importance of multi-drug therapy for multibacillary leprosy.Google Scholar
  21. 21.
    Legendre DP, Muzny CA, Swiatlo E. Hansen’s disease (Leprosy): current and future pharmacotherapy and treatment of disease-related immunologic reactions. Pharmacotherapy. 2012;32(1):27–37.CrossRefPubMedGoogle Scholar
  22. 22.
    Maia MV, Cunha Mda G, Cunha CS. Adverse effects of alternative therapy (minocycline, ofloxacin, and clofazimine) in multibacillary leprosy patients in a recognized health care unit in Manaus, Amazonas, Brazil. An Bras Dermatol. 2013;88(2):205–10.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Fajardo Jr TT et al. Minocycline in lepromatous leprosy. Int J Lepr Other Mycobact Dis. 1995;63(1):8–17.PubMedGoogle Scholar
  24. 24.
    Grosset JH. Newer drugs in leprosy. Int J Lepr Other Mycobact Dis. 2001;69(2 Suppl):S14–8.PubMedGoogle Scholar
  25. 25.
    Setia MS et al. Is there a role for rifampicin, ofloxacin and minocycline (ROM) therapy in the treatment of leprosy? Systematic review and meta-analysis. Trop Med Int Health. 2011;16(12):1541–51.CrossRefPubMedGoogle Scholar
  26. 26.
    Narang T, Arshdeep, Dogra S. Minocycline in leprosy patients with recent onset clinical nerve function impairment. Dermatol Ther. 2016. doi: 10.1111/dth.12404.
  27. 27.
    Matsuoka M. Global surveillance system to monitor the development of drug resistance in Mycobacterium leprae. Research and Reports in Tropical Medicine. 2015;6:75–83.Google Scholar
  28. 28.
    Alberts CJ et al. Potential effect of the World Health Organization’s 2011–2015 global leprosy strategy on the prevalence of grade 2 disability: a trend analysis. Bull World Health Organ. 2011;89(7):487–95.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Thappa DM. Disability grading in leprosy: current status. Indian J Lepr. 1994;66(3):299–306.PubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2016

Authors and Affiliations

  • Minh Van Hoang
    • 1
  • Duc Van Bui
    • 1
  • Thuy Linh Phung
    • 2
    Email author
  1. 1.Department of DermatologyUniversity of Medicine and Pharmacy of Ho Chi Minh CityHo Chi Minh CityVietnam
  2. 2.Department of Pathology and ImmunologyBaylor College of Medicine and Texas Children’s HospitalHoustonUSA

Personalised recommendations